Aetiology, comorbidity and drug therapy of chronic heart failure in the real world: the EPICA substudy

被引:22
作者
Ceia, F
Fonseca, C
Mota, T
Morais, H
Matias, F
Costa, C
Oliveira, AG
机构
[1] Univ Nova Lisboa, Sch Med Sci, Dept Med Therapeut, Lisbon, Portugal
[2] Hosp S Francisco Xavier, Med Serv, P-1400 Lisbon, Portugal
[3] Univ Nova Lisboa, Sch Med Sci, Dept Internal Med, Lisbon, Portugal
[4] Univ Nova Lisboa, Sch Med Sci, Dept Cardiol, Lisbon, Portugal
[5] Hosp Pulido Valente, Serv Cardiol, P-1750 Lisbon, Portugal
[6] EPICA, Grp Invest, P-1050 Lisbon, Portugal
[7] Datamed Ltd, Lisbon, Portugal
[8] Datamed, P-1200 Lisbon, Portugal
关键词
heart failure; primary care; guidelines; treatment;
D O I
10.1016/j.ejheart.2004.09.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Chronic heart failure (CHF) is common and is frequently managed by primary care physicians (PCPs). Despite the European Society of Cardiology (ESC) Guidelines, standard treatments for CHF are frequently underutilised, particularly in primary care. Aim: To evaluate current drug therapy for CHF in adults with HF diagnosed according to ESC guidelines in the context of the EPICA study. Aetiological features and therapy relevant comorbidities were also analysed. Methods: EPICA was a community-based epidemiological study conducted in mainland Portugal. The study involved 365 primary care physicians, who evaluated 6300 primary care attendees aged over 25 years. CHIF was diagnosed by clinical and echocardiography criteria according to ESC guidelines. Results: Total of 551 cases of CHF were identified, with a mean age of 65 +/- 9 years. The estimated overall prevalence of CHF in the Portuguese population was 4.4%; 1.3% with and 1.7% without left ventricular systolic dysfunction (LVSD). There are 6,280,792 people aged > 25 years in Portugal, which extrapolates to 261,400 cases of heart failure. About 80% of patients had a history of hypertension, 39% had a history of coronary artery disease and 15% had atrial fibrillation. Only 58% of patients were on angiotensin-converting enzyme (ACE) inhibitors and 7% on beta-blockers. The type of ventricular dysfunction, age and presence of renal failure had little effect on prescription rates. Diuretics were prescribed in 78%. Thiazides were used more frequently in those with preserved systolic function and frusemide in those with left ventricular systolic dysfunction. Digoxin was prescribed more often to patients with than without left ventricular systolic dysfunction (34% vs. 17%; p = 0.02). Long-acting nitrates were prescribed to 20% and amiodarone to 8% of patients. Conclusion: The EPICA study, as in other studies in primary care in Europe, particularly the IMPROVEMENT study, suggests that greater efforts are required to improve training of primary care teams in the management of CHF. (C) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:801 / 806
页数:6
相关论文
共 50 条
  • [21] Drug therapy and heart failure prevention
    Linseman, JV
    Bristow, MR
    CIRCULATION, 2003, 107 (09) : 1234 - 1236
  • [22] PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic heart failure in primary care (PREFER): a real-world study
    Hobbs, F. D. Richard
    Hussain, Rizwan, I
    Vitale, Cristina
    Pinto, Yigal M.
    Bueno, Hector
    Lequeux, Benoit
    Pauschinger, Matthias
    Obermeier, Michael
    Ferber, Philippe C.
    Gustafsson, Finn
    OPEN HEART, 2021, 8 (02):
  • [23] Pharmacoeconomic Analysis of Chronic Heart Failure Drug Therapy in Patients with Comorbid Conditions
    Zyryanov, Sergey K.
    Cheberda, Alexey E.
    Belousov, Dmitry Yu.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2018, 14 (02) : 167 - 175
  • [24] Holistic therapy of chronic heart failure
    Feldmann, C.
    Ertl, G.
    Angermann, C. E.
    INTERNIST, 2014, 55 (06): : 676 - +
  • [25] Baroreflex activation therapy in advanced heart failure therapy: insights from a real-world scenario
    Guckel, Denise
    Eitz, Thomas
    El Hamriti, Mustapha
    Braun, Martin
    Khalaph, Moneeb
    Imnadze, Guram
    Fink, Thomas
    Sciacca, Vanessa
    Sohns, Christian
    Sommer, Philipp
    Noelker, Georg
    ESC HEART FAILURE, 2023, 10 (01): : 284 - 294
  • [26] Therapy of chronic left heart failure
    Ertl, G.
    Angermann, C. E.
    INTERNIST, 2007, 48 (01): : 59 - 65
  • [27] Missed opportunities in the diagnosis of heart failure: a real-world assessment
    Ferreira, Joao Pedro
    Taveira-Gomes, Tiago
    Canelas-Pais, Mariana
    Phan, Phillip
    Bernardo, Filipa
    Sundell, Karolina Andersson
    Almeida, Mario
    Martinho, Hugo
    Gavina, Cristina
    ESC HEART FAILURE, 2023, 10 (06): : 3438 - 3445
  • [28] Mismatch between heart failure patients in clinical trials and the real world
    Niederseer, David
    Thaler, Christoph W.
    Niederseer, Michaela
    Niebauer, Josef
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (03) : 1859 - 1865
  • [29] Pharmacologic Therapy of Chronic Heart Failure
    Eman Hamad
    Paul J. Mather
    Siva Srinivasan
    Sharon Rubin
    David J. Whellan
    Arthur M. Feldman
    American Journal of Cardiovascular Drugs, 2007, 7 : 235 - 248
  • [30] Eligibility for vericiguat in a real-world, contemporary heart failure population
    Vergaro, Giuseppe
    Aimo, Alberto
    Gentile, Francesco
    Mandoli, Giulia Elena
    Focardi, Marta
    Castiglione, Vincenzo
    Giannoni, Alberto
    Panichella, Giorgia
    Fornaro, Alessandra
    Carluccio, Erberto
    Liga, Riccardo
    Salatin, Mattia
    Passino, Claudio
    Piepoli, Massimo F.
    Cameli, Matteo
    Cappelli, Francesco
    Di Mario, Carlo
    Emdin, Michele
    ESC HEART FAILURE, 2024, 11 (06): : 3523 - 3529